ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Analysis of L Antigen Family Member 3 as a Potential Biomarker and Therapeutic Target Associated With the Progression of Hepatocellular Carcinoma

Chen, Qianhui; Lu, Xinyu; Xie, Jiayi; Ma, Na; Xu, Weikang; Zhang, Zhiming; Huang, Xuan; Liu, Hongyan; Hou, Jinlin*; Zhang, Xiaoyong*; Zhu, Wei*佛山市第一人民医院; 南方医科大学
Frontiers in Oncology2022-3-31DOI: 10.3389/fonc.2022.813275
1被引6阅读
引用收藏
分享

摘要

BackgroundHepatocellular carcinoma (HCC) is the third cause of cancer-related deaths worldwide. L antigen family member 3 (LAGE3) is a prognostic biomarker and associated with progression in a variety of tumors. However, little has been reported about the role and potential mechanism of LAGE3 in HCC. MethodsThe clinical value and function of LAGE3 in HCC were obtained from multiple online databases. The potential functions and pathways of LAGE3 in HCC were analysed by R package of "clusterProfiler". LAGE3 knockdown cells were constructed in HepG2, HuH7 and MHCC97H cell lines, respectively. The biological roles of LAGE3 were examined by in vitro and in vivo experiments. ResultsLAGE3 was upregulated in HCC tissues compared with normal tissues, and high expression of LAGE3 was significantly associated with several clinical characteristics and indicated a worse prognosis of HCC. The co-expressed genes of LAGE3 could be enriched in the mTOR signaling pathway in HCC. LAGE3 was upregulated in HCC cell lines. Functionally, knocking down LAGE3 expression not only increased apoptosis and inhibited growth rate, cell death mediated by T cells, colony formation, migration and invasion ability of HCC cell lines in vitro, but also reduced the progression of HCC in the subcutaneous xenotransplanted tumor model. ConclusionOur results suggested that LAGE3 served as an oncogenic factor of HCC and could be a potential biomarker and therapeutic target for HCC.

学科与关键词

关键词
hepatocellular carcinomaL antigen family member 3biological functiontherapeutic targetbiomarkertumorigenicity
相关
加载中…
  • Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication
    Zhao, Zhen; Zheng, Zehao; Huang, Jianfeng; Wang, Jianxi; Peng, Tianyi; Lin, Ye*; Jian, Zhixiang*Frontiers in Molecular Biosciences, 2022, 9: 816102.被引 2
  • Identification of PAFAH1B3 as Candidate Prognosis Marker and Potential Therapeutic Target for Hepatocellular Carcinoma
    Xu, Weikang; Lu, Xinyu; Liu, Jing; Chen, Qianhui; Huang, Xuan; Huang, Kuiyuan; Liu, Hongyan*; Zhu, Wei*; Zhang, Xiaoyong*Frontiers in Oncology, 2021, 11.被引 4
  • A prospective diagnostic and prognostic biomarker for hepatocellular carcinoma that functions in glucose metabolism regulation: Solute carrier family 37 member 3
    Meng, Ziyu; Geng, Xue; Lin, Xiaoyue; Wang, Ziwei; Chen, Danchun; Liang, Hua; Zhu, Ying; Sui, Yutong*Biochimica et Biophysica Acta - Molecular Basis of Disease, 2023, 1869(4): 166661.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-03-31
卷期
第 12 卷
页码
813275
DOI
10.3389/fonc.2022.813275
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82073360, 81802449]; China Postdoctoral Science Foundation [2020M672739, 2020T130281]

作者

  • C

    Chen, Qianhui (第一作者)

    southern med univ

  • L

    Lu, Xinyu

    southern med univ

查看全部 11 位作者收起作者
  • X

    Xie, Jiayi

    southern med univ

  • M

    Ma, Na

    first peoples hosp foshan

  • X

    Xu, Weikang

    southern med univ

  • Z

    Zhang, Zhiming

    southern med univ

  • H

    Huang, Xuan

    southern med univ

  • L

    Liu, Hongyan

    southern med univ

  • H

    Hou, Jinlin (通讯)

    southern med univ

  • Z

    Zhang, Xiaoyong (通讯)

    southern med univ

  • Z

    Zhu, Wei (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417